The predictive value of thrombomodulin for venous thromboembolism in patients with lung cancer / 中国医师进修杂志

ABSTRACT

Objective:To explore the predictive value of thrombomodulin (TM) for venous thromboembolism (VTE) in patients with lung cancer.Methods:The clinical data of 356 patients with lung cancer from March 2020 to March 2021 in Honghu People′s Hospital were retrospectively analyzed. Among them, 71 cases were diagnosed as VTE (VTE group) and 285 cases without VTE (non-VTE group). The D-Dimer (DD), fibrinogen degradation product (FDP), prothrombin time (PT), activated partial prothrombin time (APTT), thrombin time (TT) and TM were detected. Multivariate Logistic regression analysis was used to analyze the independent risk factors of VTE in patients with lung cancer, and the receiver operating characteristic (ROC) curve was used to analyze the predictive value of TM for VTE in patients with lung cancer.Results:There were no statistical differences in FDP, PT, APTT and TT between 2 groups ( P>0.05); the TM and DD in VTE group were significantly higher than those in non-VTE group (11.61 ± 3.22) U/L vs. (7.70 ± 2.59) U/L and (5.42 ± 2.15) mg/L vs. (2.57 ± 0.96) mg/L, and there were statistical differences ( P<0.01). Multivariate Logistic regression analysis results showed that TM and DD were independent risk factors for VTE in patients with lung cancer ( OR = 0.27 and 0.66, 95% CI 0.19 to 0.39 and 0.56 to 0.78, P<0.01). ROC curve analysis result showed that the areas under curve of TM and DD for prediction VTE in patients with lung cancer were 0.830 and 0.892 (95% CI 0.772 to 0.889 and 0.842 to 0.941), and there was no statistical difference ( Z = 1.617, P>0.05); the optimum cut off values of TM and DD were 9.39 U/L and 3.83 mg/L, the sensitivity was 77.46% and 76.06%, and the specificity was 73.33% and 91.58%. Conclusions:The TM can be used as prediction index for VTE in patients with lung cancer.